ABSTRACT
BACKGROUND
Cardiovascular disease remains the leading cause of death in patients with end stage renal disease (ESRD) and accounts for approximately 45% of all deaths. 1 Cardiac risk is increased 20 -fold for those on dialysis and remains 5 -fold increased after renal transplantation. 2 Identifying markers of high risk in this patient group is therefore essential to allow improvements in diagnosis, risk stratification and treatment. Cardiac troponin T (cTnT) is elevated in a proportion of patients with ESRD and is associated with increased mortality. 3, 4 The reasons for this remain unclear. Possible mechanisms include coronary artery disease (CAD), 5 left ventricular (LV) dysfunction, LV hypertrophy, cardiac microinfarctions and arrhythmia. The aim of this study was to prospectively investigate cardiac structural and functional abnormalities in a group of patients with ESRD and relate these with cTnT level and outcome.
METHODS

Population
This was a prospective observational study in an unselected group of renal transplant candidates. One hundred and twenty nine consecutive patients referred for renal transplantation evaluation were enrolled. Three refused coronary angiography so were not included in the analysis, leaving a sample size of 126 patients. Exclusion criteria were: age less than 18 years, severe aortic stenosis, unstable angina and inability to consent. All patients had coronary angiography, including young, non diabetic patients who usually would be considered low cardiac risk and not referred for this investigation. Informed consent was required for this. The study had approval from the local ethics committee. Study entry was at the time of echocardiography. At this stage full demographic data, physical examination, haematological and biochemical blood tests were acquired. Glomerular filtration Rate (GFR) was estimated according to the Cockcroft-Gault equation: GFR = (140 -age) × ideal body weight (kg) / 72 × stable serum creatinine (µmol/L) × (0.85 for females).
Transthoracic Echocardiography
The General Electric Vingmed System 7 ultrasound machine was used. Studies were performed 16 -24 hours post dialysis, when patients were closest to their euvolaemic state. 6 Two-dimensional measurements were performed as recommended by the American Society of Echocardiography. 7 Values were indexed to body surface area. LV ejection fraction (LVEF) determined by modified biplane Simpson's rule. Measurements were averaged over three cardiac cycles. Impaired LV systolic function was defined as LVEF < 50%. 8 LV mass calculated according to Devereux. 9 This was corrected for body surface area to give LV mass index (LVMI). LV hypertrophy (LVH) was defined as LVMI ≥ 125 g/m 2 in males and LVMI ≥ 110 g/m 2 in females.
Pulsed Doppler was used to record transmitral flow in the apical 4 chamber view. Flow propagation velocity (Vp) was calculated from colour M-Mode in the apical 4 chamber view. Tissue Doppler velocities were acquired at the lateral mitral annulus. LV filling pressure estimated from E/Ea and E/Vp ratios 10 . LV diastolic dysfunction defined from the transmitral Doppler pattern as slow relaxation (E/A ratio <1, E deceleration time > 220ms), restrictive filling (E/A > 2.0, E/A between 1 and 2 with E deceleration time < 150ms), or pseudonormal (Ea < 0.08ms, Vp < 0.45m/s in the context of normal transmitral Doppler).
11
Dobutamine Stress Echocardiograpy
Images were acquired in standard parasternal long-and short-axis and apical 2-, 3-, 4-chamber views at baseline and during stepwise infusion of dobutamine infusion, given according to a protocol based on 3 minute stages of 5, 10, 20, 30, 40 µg/kg/min. Atropine was administered up to a total of 1.0 mg intravenously if the target heart rate was not achieved with dobutamine alone. Blood pressure and 12-lead ECG were recorded at each infusion stage. Baseline, low-dose (heart 10 -15 beats above baseline), peak and recovery (10 minutes after drug infusion terminated) stage images were stored and analysed in digital quad screen format. The test was stopped if: (a) the target heart rate was achieved ([220 -age] x 0.85), (b) ST depression > 2mm occurred, (c) significant tachyarrhythmia (sustained supraventricular tachycardia or a > 3 beat run of ventricular tachycardia) occurred, (d) symptomatic severe hypotension occurred, (e) blood pressure exceeded 240mmHg systolic or 140mmHg diastolic, (f) a new RWMA.
Images were reported off-line by 2 experienced observers blinded to the rest of the study. Qualitative analysis performed with the LV divided into a 17 segment model. 12 Regional wall motion described as hyperkinetic, normal, hypokinetic, akinetic and dyskinetic. Results classified as a normal response with an overall increase in wall motion or abnormal response. An abnormal response was described by the occurrence under stress of hypokinesia, akinesia, or dyskinesia in 1 or more resting normal segments and/or worsening of wall motion in 1 or more resting hypokinetic segments. 13 The peak wall motion score index (PWMSI) was calculated for each patient. All images were stored in digital format and off line measurements made by 2 experienced observers blinded to the rest of the study. Consensus was obtained in discordant cases.
cTnT and N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) Assays
Blood samples, obtained at the time of echocardiography, were drawn into gel serum separator tubes (SST tubes, Becton-Dickinson, Oxford), allowed to clot and serum was separated by centrifugation at 3000rpm for 10 minutes. Measurement of cTnT was by the third generation Elecsys 2010 STAT electrochemiluminescent immunoassay (Roche Diagnostics, Lewes).
14 The assay detection limit was < 0.01µg/L. The total assay coefficient of variation (CV) was 5.5% at 0.32 µg/L and 5.4% at 6.0 µg/L. The functional sensitivity corresponding to 10% CV was 0.03 µg/L. The receiver operator characteristic (ROC) curve medical decision cut off for myocardial infarction is 0.05µg/L with an optimise threshold of 0.1 µg/L recommended by some authors. 15 The 99 th percentile of 350 healthy subjects was ≤ 0.01µg/L. Patients were divided into 2 groups using two cut points, 0.04µg/L as the mid point between the functional sensitivity and ROC cut-off and a recommended clinical threshold value of 0.1µg/L. ESRD patients with baseline cTnT levels above either of these values are at increased risk of cardiovascular and all cause mortality.
NT-proBNP was determined by electrochemiluminescence immunoassay on the Elecsys 2010 (Roche Diagnostics, Lewes). The assay detection limit is 1 pg/mL, and is linear up to 25,000 pg/mL, with no high dose hook effect up to 100,000 pg/mL. The functional sensitivity is 10 pg/mL. At concentrations >70 pg/mL the intra-assay CV is <4%, and the inter-assay precision is <5%. A baseline NT-proBNP level ≥ 125pg/mL was taken as elevated. 16 
Coronary Angiography
This was performed in all patients. Angiograms were interpreted blindly by 2 experienced observers and consensus obtained for disagreement. Stenosis severity of each epicardial artery was assessed visually and graded as follows: No stenosis, mild (< 50% luminal narrowing), moderate (50 to 70% luminal narrowing), severe (>70% luminal narrowing). Severe CAD was defined as luminal stenosis > 70% in 1 or more epicardial artery.
Statistical Analysis
Continuous variables were expressed as mean ± 1 SD. Variables with skewed distribution were expressed as median with interquartile range. Differences between groups determined with unpaired t test. Categorical variables were compared using χ 2 analysis or Fisher's exact test. Linear regression analysis was used to assess the correlation of cTnT, as a continuous variable, with various parameters. Stepwise multiple logistic regression analysis by forward selection was used to determine independent predictors of a raised cTnT at different cut off values. Long term survival related to troponin level was analysed in a Kaplan-Meier model. The log-rank test was used to evaluate the differences between Kaplan-Meier curves. All statistical tests were two-tailed with a P value < 0.05 to indicate statistical significance. The level of agreement between 2 observers analysed using kappa statistics. The SPSS statistics package (SPSS Inc, version 12, Chicago, IL, USA) was used.
Follow-Up
This was obtained by review of inpatient and outpatient medical records and telephone calls to the transplant unit. The primary end point was total mortality.
RESULTS
Baseline Characteristics.
The clinical characteristics of the patients studied are shown in Table 1 . 69 (55%) patients were on dialysis. The mean time on dialysis was 2.73 ± 2.19 months. For those not on dialysis, mean creatinine clearance was 16 ± 9 mls/minute. 53 (42%) patients had cardiac symptoms (chest pain in 62% and shortness of breath in 38%). Medication use included aspirin in 58 patients (43%), beta blockers in 44 patients (35%), angiotensin -converting enzyme inhibitors in 54 patients (42%), statins in 63 patients (50%), erythropoetin in 53 patients (41%), loop diuretic in 56 patients (43%). * median value with interquartile range LV dimensions and systolic function were within normal limits for the population as a whole. Twenty -three patients had impaired LV function but none of these had severe impairment (LVEF < 30%). Seventy -eight patients (61%) had LVH by echo criteria. A third of the patients had severe CAD or a positive DSE result. The level of agreement, kappa (κ,) between the 2 observers was κ = 0.82 for DSE and κ = 0.85 for coronary angiography. Thirty -eight (30%) patients had cTnT ≥ 0.1µg/L and 52 (41%) had cTnT > 0.04µg/L. 74 (59%) patients had a baseline NT-proBNP level ≥ 125pg/mL. The proportion with raised NT-proBNP was significantly higher in those on dialysis compared to predialysis patients (68% vs 29% respectively, p = 0.001).
Differences in those with and without raised cTnT
Comparison of cTnT positive and negative patients was made with a cut off value 0.04µg/L and 0.10µg/L. The results are shown in table 2. Patients with an elevated cTnT had a higher proportion diabetic and on dialysis, greater LV dilatation, higher LVMI, more impaired LV systolic function, higher estimated LV filling pressures, higher NT-proBNP levels and lower cholesterol levels than those with negative cTnT. Age, sex, medication, parathyroid hormone levels and calcium -phosphate product were similar in those with and without raised cTnT. With a cut off troponin value of 0.04µg/L but not 0.10 µg/L, there were more patients with severe CAD and inducible ischaemia during DSE in the troponin positive group. The total ischaemic burden, assessed by PWMSI and total number of ischaemic segments during DSE, was similar in the troponin positive and negative patients, irrespective of the cut off value.
group 
Association of NT-proBNP and cTnT
NT-proBNP levels were significantly higher in patients with elevated cTnT at both cut-off values (see table 2 ). When compared as continuous variables, there was a significant positive correlation between cTnT and NT-proBNP (r = 0.55, p = < 0.001).
Relationship between echo parameters and cTnT concentration
Using linear regression techniques, raised cTnT levels were associated with increased LV dimensions and filling pressure but reduced systolic function. When this was analysed in the diabetic subgroup, only markers of LV filling pressure were associated with cTnT levels. These results are shown in table 3. 
Parameters independently associated with elevated cTnT
Stepwise logistic regression analysis by forward selection was performed on all the significant parameters identified by univariate analysis. The results are shown in table 4. Diabetes was an independent associate of cTnT elevation at both cut off values chosen. LVESD and E/Ea ratio were independently associated with cTnT elevation of ≥ 0.04µg/L and ≥ 0.10µg/L, respectively. Stepwise regression analysis showed that NT-proBNP levels (β = 3.2 x 10 -7 ± 10 -6 , p = 0.03) and E/Ea ratio (β = 0.003 ± 0.001, p = 0.04) best predicted cTnT concentration. Figure 1 shows Kaplan-Meier estimates of all cause mortality according to the cTnT value. Survival rates were significantly poorer in those patients with raised cTnT irrespective of the cut off value.
DISCUSSION
This study investigated clinical, biochemical, angiographic and echocardiographic parameters in the same group of ESRD patients with and without raised cTnT. These parameters were assessed at cut off cTnT values of 0.1µg/L and 0.04µg/L. These respectively correspond to the suggested cut off for acute myocardial infarction and the 10% coefficient variation cut off which is suggested to optimise laboratory precision. 17 We found that patients with elevated cTnT have increased mortality, as previously described. 3, 18 These patients were more likely to be diabetic, have LV dilatation, impaired LV systolic function and higher LV filling pressures. There was a less clear association with severe CAD.
The population studied, namely an unselected group of potential renal transplant candidates, was undoubtedly healthier than previously studied ESRD patients on long term dialysis. This referral bias meant that none of the patients had poor LV systolic function, the vast majority had normal LVEF, a large proportion were not on dialysis and there was a short duration for those on dialysis. Thus our results apply to ESRD patients with normal LVEF and may not extend to those with systolic dysfunction. However, the use of biomarkers to assess risk in ESRD is probably most relevant in those being referred for renal transplantation.
A significantly higher proportion of troponin positive patients were on dialysis. The mechanism for this remains unclear but recent evidence suggests an accumulation of cTnT fragments in the serum of dialysed patients. 19 Irrespective of the cut off value used, cTnT positive patients had significantly more dilated left ventricles than those without and more significantly impaired LV systolic and with higher estimated LV filling pressures. This is in keeping with previous studies 20 and supports the argument that 'false positive' cTnT values in renal failure represent clinically significant myocardial damage. 21 LV dysfunction and dilatation are independent predictors of mortality in ESRD. 22, 23 These echo findings may therefore at least partly explain the observed higher mortality seen in renal failure patients with elevated cTnT. LA size was significantly higher in patients with elevated troponin. This parameter is an independent marker of outcome in cardiovascular disease 24 and undoubtedly relates to increased LV filling pressures. LVMI was also higher in the cTnT positive group, another parameter known to be associated with increased mortality in ESRD. 25 It is important to note that the cardiac structural differences in the troponin positive and negative groups could not be explained by differences in medication, blood pressure, body mass index, haemoglobin or parathyroid hormone level.
In this study, 59% patients had raised NT-proBNP concentrations, as defined by the threshold value for heart failure diagnosis in non uraemic patients. NT-proBNP is predominantly excreted by the kidneys, in contrast to clearance of brain natriuretic peptide (BNP) by receptor internalisation and plasma neuropeptidase degradation. NT-proBNP may therefore be inferior to BNP in ESRD for risk stratification. Indeed, a BNP cut off concentration of 390 ng/L has been shown to predict mortality in haemodialysis patients. 26 Apple et al concluded NT-proBNP has poor prognostic ability at the threshold derived from the 99 th percentile of the reference interval. 27 However, tertile analysis from the same data suggested significant prognostic value of NT-proBNP if a higher cut off value was used. This would suggest raised NTproBNP levels in renal failure are not simply a reflection of impaired excretion. Further studies are required to clarify this. Recently, DeFillipi et al. showed that NTproBNP level elevation in asymptomatic chronic kidney disease patients not on dialysis reflects CAD and LVH independent of renal function. 28 In our study, the positive correlation between NT-proBNP and cTnT reflects, in part, the raised LV filling pressure and impaired systolic function of the cTnT positive patients. However, the strong association of NT-proBNP with dialysis, as previously reported, 29 suggests dialysis may be a factor in the cardiac structural differences seen in troponin positive and negative patients because of greater cardiac injury, higher LV filling pressure, reduced clearance or all 3.
The mechanisms causing the observed cardiac abnormalities in ESRD patients with elevated troponin remain unclear. In experimental models of renal failure, cardiac function is impaired with microvascular changes and LV hypertrophy associated with reduced capillary density. 30 These functional and anatomical changes may contribute to susceptibility to ischaemic injury. In autopsied ESRD cases, elevated cTnT was associated with recent acute myocardial infarction or microinfarcts, heart failure or other myocardial damage. 31 Some have suggested an association with CAD. 32 In our study, only with a cut off value of 0.04µg/l, was there a significant difference in cTnT positive and negative patients for severe CAD and inducible ischaemia. At a value of 0.10µg/l this difference was lost. Moreover, the total ischaemic burden during DSE was similar in those with and without raised troponin, irrespective of the cut off value used. CAD or a positive DSE result were not independently associated with a raised cTnT. This would suggest the structural cardiac differences and subsequent increased mortality seen in ESRD patients with elevated troponin are not explained by the presence of severe CAD alone. This is in keeping with the results of Obialo et al. 32 DeFilippi et al. 33 noted an association with cTnT level and diffuse CAD in 67 patients with ESRD. However, the cTnT concentration was below the threshold for myocardial necrosis. In our study, serum cholesterol was significantly lower in the troponin positive patients despite similar use of statins in each group. The reasons for this are unclear but may be related to poorer nutritional status of those with elevated troponin. Other potential mechanisms for cardiac injury in ESRD include microinfarction and myocarditis but these have yet to be substantiated by clinical studies.
Diabetes remained independently associated with elevated cTnT, irrespective of the cut off value. This was found in 2 previous studies 3, 20 but contrasts with the findings of Apple et al. 4 Diabetics with ESRD have a high prevalence of CAD. Moreover, this coronary risk factor results in functional, biochemical and morphological cardiac abnormalities independent of ischaemia. 34 There is also a strong association between microvascular disease and diabetes. 35 These factors may contribute to the increased mortality and observed cardiac damage in ESRD patients with elevated troponin.
A role for troponin in the risk stratification of ESRD patients, particularly those referred for renal transplantation, is attractive. A multi -biomarker risk stratification model, including troponin, has recently been proposed. 27 Given the poorer prognosis associated with an elevated troponin in renal failure, tighter control of fluid shifts during dialysis and greater use of ACE inhibitors could be advocated in this patient group. However, further prospective studies are required to determine whether any intervention will improve long term mortality in troponin positive ESRD patients.
Study Limitations
This was a small, observational study so conclusions regarding mortality must be made with caution. The population selected was heterogenous in nature and comprised dialysis and non dialysis patients. Nevertheless, this is representative of renal transplant candidates in whom cardiac risk assessment is important. Given the changes that occur in hydration status between dialysis sessions, echo parameters and biochemical markers should be measured at similar times after dialysis if comparisons are to be made. In this study, all measurements were made 16 -24 hours after dialysis. 6 Finally, as discussed earlier, BNP, being a smaller molecule than NTproBNP and not reliant on renal clearance, may have been better for examining the relationship between troponin and natriuretic peptides.
Conclusions
In an unselected group of renal transplant candidates, patients with elevated cTnT had clear evidence of myocardial dysfunction as evidenced by LV dilatation, impaired LV systolic function and raised LV filling pressure. Severe CAD did not appear to be centrally involved in cTnT elevation but there was a strong association with diabetes. These findings may, at least in part, explain the observed higher mortality of ESRD patients with elevated troponin. Figure. 1. Kaplan -Meier Survival Curves According to cTnT Concentration.
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